HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 888-259-6580 within the U.S. or +1 416-764-8624 outside the U.S., ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET Company Participants Edward Chung - Head, IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andy Last - EVP and COO Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Jack Meehan - Nephron Tim Daley - Wells Fargo Conor McNamara - RBC Capital Operator Good afternoon, ladies and gentlemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-138 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Brandon Couillard - Jefferies Tim ...

Common Shares Outstanding at July 28, 2023: Class A - 24,004,023 Class B - 5,072,204 BIO-RAD LABORATORIES, INC. Condensed Consolidated Balance Sheets (continued) (In thousands, except share data) | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------------|----- ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Ed Chung - Vice President, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Dan L ...

Available-for-sale investments consist of the following (in millions): March 31, 2023 17 The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2023 by contractual maturity date (in millions): 38 We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the three months ended March 31, 2023 our foreign entities generated 56% of our net sales. Compliance with complex fore ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Company Participants Edward Chung - Vice President, Investor Relations Ilan Daskal - Chief Financial Officer Andrew Last - Chief Operating Officer Norman Schwartz - President and Chief Executive Officer Simon May - President, Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Inc. Dan Leonard - Credit Suisse Brandon Couillard - Jefferies Group LLC Jack Meehan - Nephron Research LLC O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year endedDecember 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charte ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Dara Wright - EVP & President, Clinical Diagnostics Group Simon May - EVP & President, the Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Brandon Couillard - Jefferies Daniel Leonard - Crédit Suisse Jack Meehan - Nephron Research Operator Good even ...